Bausch & Lomb v. Slayback Pharma: Lumify® Brimonidine Patent Case Stayed After 1,174 Days
Bausch & Lomb brought a patent infringement action against Slayback Pharma over its generic brimonidine tartrate 0.025% ophthalmic solution — directly challenging the IP protecting Lumify® eye drops. After over three years of district court proceedings, the New Jersey court granted a stay pending resolution of two PTAB inter partes review proceedings, administratively closing the matter in November 2024.
Lumify® Generic Challenge Halted Pending Dual PTAB IPR Review
Bausch & Lomb, Inc., together with Bausch & Lomb Ireland Limited and Eye Therapies, LLC, filed this infringement action in the District of New Jersey on September 10, 2021, asserting US9259425B2 and US8293742B2 against Slayback Pharma LLC and associated Dr. Reddy’s Laboratories entities. The patents cover brimonidine tartrate ophthalmic formulations, and the accused product is Slayback’s ANDA-referenced generic version of Lumify® — Bausch & Lomb’s commercially significant over-the-counter eye redness relief product containing brimonidine tartrate at 0.025%.
After more than three years of litigation, the defendants moved to stay the district court proceedings pending resolution of two inter partes review petitions filed at the Patent Trial and Appeal Board. On November 27, 2024, the court granted that motion, staying all proceedings and directing the parties to file a joint status letter by May 1, 2025 regarding PTAB and/or Federal Circuit progress. The Clerk was ordered to administratively close the matter, meaning no final judgment on infringement or validity has been entered.
The 1,174-day duration before the stay reflects the complexity typical of Hatch-Waxman ophthalmic cases involving multiple defendants and parallel PTAB proceedings. The administrative closure does not resolve the underlying infringement dispute — Slayback’s generic product remains at risk if the patents survive IPR, and Bausch & Lomb retains the ability to reinstate the case. The public record does not disclose whether any licensing discussions have occurred or what the PTAB institution status was at the time of the stay grant.
Filing to Case Stayed in 1174 days
1,174 days in D.N.J. before administrative stay — above median ANDA patent case duration
Court-ordered stay: what the administrative closure means for both parties
A stay is not a dismissal — litigation is paused, not ended
An administrative stay with closure is a docket-management tool: the district court retains jurisdiction and the case can be reopened. The court found good cause — consistent with the standard factors of simplification of issues, stage of litigation, and prejudice to the non-movant — to pause proceedings while PTAB evaluates the validity of the asserted patents. No merits ruling has been made on infringement or validity.
Proceedings suspendedBausch & Lomb faces validity uncertainty through PTAB proceedings
For Bausch & Lomb, the stay means the district court infringement action is on hold while PTAB assesses the core validity of the two Lumify® patents. If the IPR proceedings result in cancellation of key claims, the district court case may be rendered moot. The patents remain presumptively valid during this period, but commercial enforcement against Slayback’s generic product is effectively paused.
Enforcement pausedSlayback gains procedural breathing room via PTAB route
Slayback and the Dr. Reddy’s entities successfully shifted the validity contest to PTAB — a forum that historically applies a lower burden and broader claim construction standard. A favorable IPR outcome could invalidate one or both asserted patents, eliminating the infringement claims entirely. The stay insulates Slayback from district court discovery costs and potential injunctions while PTAB proceedings run their course.
PTAB challenge activeLumify® market exclusivity hinges on PTAB outcomes
Lumify® is a commercially significant OTC ophthalmic product. The patent stay effectively defers generic market entry risk, but also defers resolution for Bausch & Lomb. If PTAB cancels claims, the district court case collapses and the generic path opens. If claims survive, the stayed litigation resumes with strengthened patent posture. Competitors monitoring this case should track PTAB dockets for IPR institution and final written decision milestones.
Market entry deferredFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bausch & Lomb, Inc. | Company | Ophthalmic pharmaceutical company — holder of US9259425B2 and US8293742B2 (Lumify®)Search in Eureka ↗ |
| Defendant | Slayback Pharma, LLC | Company | Generic pharmaceutical manufacturer seeking ANDA approval for brimonidine tartrate 0.025% ophthalmic solutionSearch in Eureka ↗ |
| Plaintiff counsel | Bryan C. Diner | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE N. CRAFT | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Justin James Hasford | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stephen R. Donat | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | Law Firm | Representing Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Bausch & Lomb, Inc.Search in Eureka ↗ |
| Defendant counsel | Anandita Vyakarnam | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | Frank D. Rodriguez | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | LOUIS HARRY WEINSTEIN | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing Slayback Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order grants a stay rather than resolving the merits — no finding of infringement or invalidity has been made. The language ‘for good cause shown’ reflects the court’s exercise of inherent docket-management discretion, applying the standard three-factor stay analysis. The explicit requirement for a joint PTAB/Federal Circuit status letter by May 2025 suggests the court anticipates active monitoring of the parallel IPR proceedings, and that the stay may be modified or lifted depending on PTAB outcomes.
US9259425B2 & US8293742B2 — Brimonidine Tartrate Ophthalmic Formulations (Lumify®)
US9259425B2 and US8293742B2 both relate to ophthalmic formulations of brimonidine tartrate, specifically at the low concentration of 0.025% — the active ingredient in Lumify®. Brimonidine is an alpha-2 adrenergic agonist historically used at higher concentrations (0.1%–0.2%) for glaucoma management; the innovation claimed in these patents relates to its use and formulation at markedly lower doses for cosmetic redness relief. The application underlying US8293742B2 was filed in 2010, making the patent portfolio approximately 14 years old at the time of the stay.
These patents sit at a commercially sensitive intersection: Lumify® is one of the few OTC ophthalmic products with a genuinely differentiated mechanism compared to older vasoconstrictors, commanding significant retail shelf presence. A successful IPR challenge against either patent would open the door to generic competition and place significant pricing pressure on the brand product. Any company developing or marketing brimonidine-based ophthalmic formulations — even at different concentrations or for adjacent indications — should closely track claim scope and PTAB outcomes for both patents.
Should you run an FTO against US9259425B2 and US8293742B2?
Any pharmaceutical or medical device company developing a brimonidine tartrate ophthalmic product — particularly at concentrations at or near 0.025% — should treat these two patents as live freedom-to-operate risks. The stay does not invalidate the patents; they remain in force. ANDA filers, 505(b)(2) applicants, and companies developing combination ophthalmic drops containing alpha-2 agonists should assess claim scope carefully before formulation finalization.
PatSnap Eureka’s FTO Search Agent can map the claim boundaries of US9259425B2 and US8293742B2 against your product formulation parameters — including concentration ranges, excipient profiles, and indication targets. Eureka also monitors live PTAB dockets, so your FTO analysis updates automatically when IPR institution decisions or final written decisions issue — critical for this case where PTAB outcomes will directly determine whether district court litigation resumes.
Run a freedom-to-operate analysis on US9259425B2 to assess your product’s exposure
Run FTO in Eureka →Similar Ophthalmic Pharma Patent Cases in D.N.J. and PTAB-Stayed Hatch-Waxman Matters
Explore related Hatch-Waxman infringement actions involving ophthalmic formulation patents in the District of New Jersey with parallel PTAB IPR proceedings.
What this case signals for the ophthalmic pharmaceutical IP landscape
This stay underscores the growing strategic role of IPR petitions as leverage tools in Hatch-Waxman ophthalmic patent disputes.
PTAB filing can displace district court proceedings even mid-litigation
Defendants here successfully obtained a stay more than three years into litigation — demonstrating that IPR petitions filed late in the case lifecycle can still shift the primary forum. Plaintiffs holding ophthalmic formulation patents should factor in PTAB exposure from filing day, not just at institution.
Dual-patent assertions complicate IPR strategy for generic challengers
With two patents in suit — US9259425B2 and US8293742B2 — Slayback needed IPR proceedings covering both to justify a comprehensive stay. Patent holders asserting multiple formulation patents can sometimes foreclose a clean stay by staggering patent strength, making it harder for challengers to consolidate PTAB and district court timelines.
Bausch v Slayback — key questions answered
The court administratively closed the case on November 27, 2024, suspending all district court proceedings pending resolution of two IPR proceedings before PTAB. No final judgment on infringement or validity was issued. The stay is not a dismissal — the court retains jurisdiction and may reopen the case once PTAB issues final written decisions or the Federal Circuit completes any related appeals.
Bausch & Lomb asserted US9259425B2 and US8293742B2, both covering brimonidine tartrate ophthalmic formulations at low concentrations. These patents underpin Lumify® — a 0.025% brimonidine tartrate OTC ophthalmic solution indicated for ocular redness relief. Both patents are currently subject to IPR proceedings before PTAB that triggered the district court stay.
The court found good cause to stay proceedings based on the pendency of two IPR petitions challenging the asserted patents at PTAB. Courts typically weigh three factors: simplification of issues by the PTAB proceeding, stage of the litigation, and undue prejudice to the non-movant. The court’s order does not detail its balancing, but granting the stay suggests it found PTAB proceedings sufficiently advanced to justify pausing district court litigation.
If PTAB cancels the asserted claims of US9259425B2 or US8293742B2 in the IPR proceedings, Bausch & Lomb would lose the basis for its infringement claims against Slayback in the district court. The stayed case would likely be dismissed, clearing the path for Slayback’s generic brimonidine tartrate 0.025% ophthalmic product to enter the market subject to FDA approval.
Plaintiffs are Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC. Defendants include Slayback Pharma LLC, Slayback Pharma India LLP, Dr. Reddy’s Laboratories, Inc., and Dr. Reddy’s Laboratories S.A. Plaintiff counsel includes Finnegan Henderson and Gibbons PC; defendant counsel is Windels Marx Lane & Mittendorf, LLP.
PatSnap Eureka searches patents and litigation data to answer instantly.